Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fexofenadine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Fexofenadine. Displaying page 1 of 1.
    EudraCT Number: 2017-000239-15 Sponsor Protocol Number: SFY10717 Start Date*: 2017-03-20
    Sponsor Name:Sanofi
    Full Title: An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with perennial all...
    Medical condition: Rhinitis perennial
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039094 Rhinitis perennial PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004885-27 Sponsor Protocol Number: FFU109045 Start Date*: 2016-12-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis
    Medical condition: Seasonal allergic rhinitis (SAR)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004873-34 Sponsor Protocol Number: FFU109047 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000251-74 Sponsor Protocol Number: SFY10718 Start Date*: 2017-03-20
    Sponsor Name:Sanofi
    Full Title: An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with atopic dermat...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003004-19 Sponsor Protocol Number: BILA-2306/ACC Start Date*: 2006-09-26
    Sponsor Name:FAES Farma S.A.
    Full Title: A randomised, double-blind, four way cross-over, placebo controlled trial to evaluate the clinical efficacy, onset of action and drug activity at 22-26 hours following the drug intake of Bilastne 2...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004158-33 Sponsor Protocol Number: CYP3A4/5+PGPinRenalTx Start Date*: 2008-09-17
    Sponsor Name:Department of Nephrology and Renal Transplantation, KU Leuven
    Full Title: CYP3A4/5 and PGP activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and...
    Medical condition: Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant med...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007657-31 Sponsor Protocol Number: MIARCU 01/2008 Start Date*: 2008-06-23
    Sponsor Name:Charité-University Berlin
    Full Title: Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria
    Medical condition: Urticaria characterized by mast cell and histamine-dependent wheal and flair type-skin responses associated with severe pruritus. The disease is very common and not always easy to treat. Mainstay t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-06-29
    Sponsor Name:HUTCHMED Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Ongoing) IT (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2006-005713-35 Sponsor Protocol Number: RPE 04 Start Date*: 2007-03-20
    Sponsor Name:Curalogic A/S
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL MICROENCAPSULATED RAGWEED POLLEN EXTRACT ADMINISTERED PRIOR TO AND DURING THE RAGWEED ...
    Medical condition: Treatment of seasonal allergic rhinitis to ragweed pollen.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA